152 related articles for article (PubMed ID: 31381134)
1. Optimizing T-cell receptor avidity with somatic hypermutation.
Bassan D; Gozlan YM; Sharbi-Yunger A; Tzehoval E; Eisenbach L
Int J Cancer; 2019 Nov; 145(10):2816-2826. PubMed ID: 31381134
[TBL] [Abstract][Full Text] [Related]
2. Avidity optimization of a MAGE-A1-specific TCR with somatic hypermutation.
Bassan D; Gozlan YM; Sharbi-Yunger A; Tzehoval E; Greenstein E; Bitan L; Friedman N; Eisenbach L
Eur J Immunol; 2021 Jun; 51(6):1505-1518. PubMed ID: 33835499
[TBL] [Abstract][Full Text] [Related]
3. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
4. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
5. Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Kerkar SP; Sanchez-Perez L; Yang S; Borman ZA; Muranski P; Ji Y; Chinnasamy D; Kaiser AD; Hinrichs CS; Klebanoff CA; Scott CD; Gattinoni L; Morgan RA; Rosenberg SA; Restifo NP
J Immunother; 2011 May; 34(4):343-52. PubMed ID: 21499127
[TBL] [Abstract][Full Text] [Related]
6. Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.
Höfflin S; Prommersberger S; Uslu U; Schuler G; Schmidt CW; Lennerz V; Dörrie J; Schaft N
Cancer Biol Ther; 2015; 16(9):1323-31. PubMed ID: 26178065
[TBL] [Abstract][Full Text] [Related]
7. Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading.
Xin G; Khatun A; Topchyan P; Zander R; Volberding PJ; Chen Y; Shen J; Fu C; Jiang A; See WA; Cui W
Cancer Immunol Res; 2020 Jan; 8(1):7-18. PubMed ID: 31719059
[TBL] [Abstract][Full Text] [Related]
8. Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing.
Ouchi Y; Patil A; Tamura Y; Nishimasu H; Negishi A; Paul SK; Takemura N; Satoh T; Kimura Y; Kurachi M; Nureki O; Nakai K; Kiyono H; Uematsu S
Int Immunol; 2018 Apr; 30(4):141-154. PubMed ID: 29617862
[TBL] [Abstract][Full Text] [Related]
9. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
Landoni E; Smith CC; Fucá G; Chen Y; Sun C; Vincent BG; Metelitsa LS; Dotti G; Savoldo B
Cancer Immunol Res; 2020 Jan; 8(1):57-69. PubMed ID: 31719055
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.
Fujiki F; Morimoto S; Nishida Y; Tanii S; Aoyama N; Inatome M; Inoue K; Katsuhara A; Nakajima H; Nakata J; Nishida S; Tsuboi A; Oka Y; Oji Y; Sogo S; Sugiyama H
Cancer Immunol Immunother; 2023 Jul; 72(7):2347-2356. PubMed ID: 36939853
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice.
Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A
Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218
[TBL] [Abstract][Full Text] [Related]
12. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy.
Zhong S; Malecek K; Johnson LA; Yu Z; Vega-Saenz de Miera E; Darvishian F; McGary K; Huang K; Boyer J; Corse E; Shao Y; Rosenberg SA; Restifo NP; Osman I; Krogsgaard M
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6973-8. PubMed ID: 23576742
[TBL] [Abstract][Full Text] [Related]
13. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
14. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
[TBL] [Abstract][Full Text] [Related]
15. Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy.
Simon B; Harrer DC; Thirion C; Schuler-Thurner B; Schuler G; Uslu U
J Immunol Methods; 2019 Sep; 472():55-64. PubMed ID: 31207210
[TBL] [Abstract][Full Text] [Related]
16. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
[TBL] [Abstract][Full Text] [Related]
18. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
19. Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis.
Han F; Dellacecca ER; Barse LW; Cosgrove C; Henning SW; Ankney CM; Jaishankar D; Yemelyanov A; Krymskaya VP; Dilling DF; Le Poole IC
Am J Respir Cell Mol Biol; 2020 Jun; 62(6):793-804. PubMed ID: 32078336
[TBL] [Abstract][Full Text] [Related]
20. Optimization of T-cell Receptor-Modified T Cells for Cancer Therapy.
Drakes DJ; Rafiq S; Purdon TJ; Lopez AV; Chandran SS; Klebanoff CA; Brentjens RJ
Cancer Immunol Res; 2020 Jun; 8(6):743-755. PubMed ID: 32209638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]